Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 10/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | POLG | P54098 | 2/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820814 | 0.87 | ALDH1A1 (0.49) | PNPALDH1A1 | |
| SCHEMBL28335557 | 0.78 | ALDH1A1 (0.44) | PNPALDH1A1POLBPOLGPOLA1 | |
| SCHEMBL4957491 | 0.78 | PNP (0.39) | PNPALDH1A1 | |
| SCHEMBL3085105 | 0.76 | PNP (0.38) | PNPALDH1A1 | |
| SCHEMBL28333212 | 0.76 | ALDH1A1 (0.42) | PNPALDH1A1POLBPOLGPOLA1 | |
| SCHEMBL27461265 | 0.75 | PNP (0.38) | PNPALDH1A1 | |
| SCHEMBL6680764 | 0.73 | HPRT1 (0.38) | PNPALDH1A1HPRT1 | |
| SCHEMBL618978 | 0.72 | PNP (0.44) | PNPALDH1A1POLB | |
| SCHEMBL27947874 | 0.71 | HPRT1 (0.54) | PNPHPRT1POLBPOLGPOLA1 | |
| SCHEMBL2352519 | 0.71 | PNP (0.43) | PNPALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218731-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | CLEAR CREEK BIO INC (US) | 2022-07-14 | — | — | US | claimed |
| WO-2020236502-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | Clear Creek Bio, Inc. (US) | 2020-11-26 | — | — | WO | claimed |
| US-20260116994-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | PREC BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12584099-B2 | Method for preparing cultures of lactic acid bacteria | CHR. HANSEN A/S (DK) | 2026-03-24 | — | — | US | disclosed |
| US-20260015432-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | PREC BIOLOGICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12460013-B2 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | PRECISION BIOLOGICS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12344676-B2 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | PRECISION BIOLOGICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025105871-A1 | GENE EDITING TREATMENT METHOD AND THERAPEUTIC AGENT FOR RETINITIS PIGMENTOSA | 재단법인 아산사회복지재단 | 2025-05-22 | — | — | WO | disclosed |
| US-20250049753-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS | OKAVA PHARMACEUTICALS INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240368532-A1 | METHOD FOR PREPARING CULTURES OF LACTIC ACID BACTERIA | CHR. HANSEN A/S (DK) | 2024-11-07 | — | — | US | disclosed |
| US-20240343825-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | PREC BIOLOGICS INC (US) | 2024-10-17 | — | — | US | disclosed |
| WO-1989011538-A1 | PLATELET-SPECIFIC CHIMERIC IMMUNOGLOBULIN | CENTOCOR, INC. (US) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989008716-A1 | NOVEL RECOMBINANT VACCINIA VIRUS EXPRESSION VECTORS AND METHOD OF SELECTING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0322417-A1 | EMPTY VIRAL CAPSID VACCINES | APPLIED BIOTECHNOLOGY, INC. (US) | 1989-07-05 | — | — | EP | disclosed |
| WO-1989004872-A1 | IMMUNOREACTIVE HETEROCHAIN ANTIBODIES | CENTOCOR, INC. (US) | 1989-06-01 | — | — | WO | disclosed |
| WO-1988009181-A2 | MONOCLONAL ANTIBODIES NEUTRALIZING HIV-1 | TANOX BIOSYSTEMS, INC. (US) | 1988-12-01 | — | — | WO | disclosed |
| WO-1988002026-A1 | EMPTY VIRAL CAPSID VACCINES | APPLIED BIOTECHNOLOGY, INC. (US) | 1988-03-24 | — | — | WO | disclosed |
| WO-1988002022-A1 | RECOMBINANT POXVIRUSES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 1988-03-24 | — | — | WO | disclosed |
| EP-0256654-A2 | Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen | CENTOCOR, INC. (US) | 1988-02-24 | — | — | EP | disclosed |
| US-4550186-A | ANTITUMOR, ANTILIPEMIC, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS | DUKE UNIVERSITY (US) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116994-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | IGSF11, IGLV6-57, VSIG8 | PNP 3511/4885ALDH1A1 4490/4885HPRT1 4342/4885 |
| US-20250049753-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS | CD47, TPMT, HLA-C | PNP 210/4885ALDH1A1 1644/4885HPRT1 387/4885 |
| US-20260015432-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | VIP, IAPP, RNASE1 | PNP 948/4885ALDH1A1 4201/4885HPRT1 4283/4885 |
| US-12584099-B2 | Method for preparing cultures of lactic acid bacteria | LCT, S100A10, RPLP0 | PNP 1100/4885ALDH1A1 1139/4885HPRT1 1530/4885 |
| US-20220218731-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | PCK2, PC, FOLR2 | PNP 1680/4885ALDH1A1 146/4885HPRT1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.